Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 9, Issue 398, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aal5272
Keywords
-
Categories
Funding
- NIH [R01CA068490, P50CA101942]
- Friends of Dana-Farber
- NIH [Cancer Biology Training grant] [T32CA009361]
- NIH [DF/HCC (Dana-Farber/Harvard Cancer Center) Kidney SPORE (Specialized Programs of Research Excellence) Career Enhancement Program award)] [P50CA101942]
- American Cancer Society Postdoctoral Fellowship [PF-14-144-01-TBE]
- Grants-in-Aid for Scientific Research [17H04328] Funding Source: KAKEN
Ask authors/readers for more resources
Inactivation of the von Hippel-Lindau tumor suppressor protein (pVHL) is the signature lesion in the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC). pVHL loss causes the transcriptional activation of hypoxia-inducible factor (HIF) target genes, including many genes that encode histone lysine demethylases. Moreover, chromatin regulators are frequently mutated in this disease. We found that ccRCC displays increased H3K27 acetylation and a shift toward mono-or unmethylated H3K27 caused by an HIF-dependent increase in H3K27 demethylase activity. Using a focused short hairpin RNA library, as well as CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) and a pharmacological inhibitor, we discovered that pVHL-defective ccRCC cells are hyperdependent on the H3K27 methyltransferase EZH1 for survival. Therefore, targeting EZH1 could be therapeutically useful in ccRCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available